Gene-corrected lung immune cells for a rare lung disease
Part of Lungs & breathing clinical trials.
This early-phase study tests a treatment that uses gene-corrected immune cells to treat hPAP, a rare lung condition. The goal is to check safety and see whether the treatment improves breathing and lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed hPAP based on specific genetic testing and lab test results for lung immune signaling (GM-CSF) and STAT5-PI (explained by the study as required patterns).
- A chest CT scan shows widespread “ground-glass” changes in the lungs.
- You have either had prior Whole Lung Lavage (WLL) treatment or your lung disease is considered moderate enough to need treatment.
- You can safely have bone marrow taken using a routine aspiration procedure.
- You’re age 18 or older and can sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study keeps a national record of people with pulmonary alveolar proteinosis (PAP). It includes one “snapshot” group and one group that follows people with autoimmune PAP and asks about symptoms and quality of life.
This program provides an experimental inhaled medication to people with a rare lung condition called autoimmune pulmonary alveolar proteinosis (aPAP), where the immune system attacks the lungs. The treatment, molgramostim, is given through a nebulizer and may help improve breathing and reduce symptoms.
This trial tests a new way to deliver a protein called GM-CSF directly into the lungs through a tube during a bronchoscopy. It may help people with autoimmune pulmonary alveolar proteinosis (aPAP) breathe better and improve lung function.
This study tests an inhaled medicine called molgramostim for children with autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition. The goal is to see if the drug can improve lung function and reduce the need for whole lung lavage (a washing procedure).
This trial uses your own cells to create stem cells (iPSCs) that can be genetically corrected to treat severe Alpha-1 Antitrypsin Deficiency. It is an early study exploring a potential cure.
This trial tests a gene therapy for people with alpha-1 antitrypsin deficiency who have mild to moderate lung disease. The aim is to see if the treatment can improve lung health and is safe.
Hear when a new Hereditary Pulmonary Alveolar Proteinosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.